Supramaximal Resection Can Prolong the Survival of Patients with Cortical Glioblastoma: A Volumetric Study

Overview

Journal Neurol Med Chir (Tokyo)

Specialties Neurology
Neurosurgery

Date 2023 Jul 9

PMID 37423755

Authors

Ryosuke Otsuji

Nobuhiro Hata

Yusuke Funakoshi

Daisuke Kuga

Osamu Togao

Ryusuke Hatae

Yuhei Sangatsuda

Yutaka Fujioka

Kosuke Takigawa

Aki Sako

Kazufumi Kikuchi

Tadamasa Yoshitake

Hidetaka Yamamoto

Masahiro Mizoguchi

Koji Yoshimoto

Affiliations

Soon will be listed here.

Abstract

We aimed to retrospectively determine the resection rate of fluid-attenuated inversion recovery (FLAIR) lesions to evaluate the clinical effects of supramaximal resection (SMR) on the survival of patients with glioblastoma (GBM). Thirty-three adults with newly diagnosed GBM who underwent gross total tumor resection were enrolled. The tumors were classified into cortical and deep-seated groups according to their contact with the cortical gray matter. Pre- and postoperative FLAIR and gadolinium-enhanced T1-weighted imaging tumor volumes were measured using a three-dimensional imaging volume analyzer, and the resection rate was calculated. To evaluate the association between SMR rate and outcome, we subdivided patients whose tumors were totally resected into the SMR and non-SMR groups by moving the threshold value of SMR in 10% increments from 0% and compared their overall survival (OS) change. An improvement in OS was observed when the threshold value of SMR was 30% or more. In the cortical group (n = 23), SMR (n = 8) tended to prolong OS compared with gross total resection (GTR) (n = 15), with the median OS of 69.6 and 22.1 months, respectively (p = 0.0945). Contrastingly, in the deep-seated group (n = 10), SMR (n = 4) significantly shortened OS compared with GTR (n = 6), with median OS of 10.2 and 27.9 months, respectively (p = 0.0221). SMR could help prolong OS in patients with cortical GBM when 30% or more volume reduction is achieved in FLAIR lesions, although the impact of SMR for deep-seated GBM must be validated in larger cohorts.

Citing Articles

Level I and II deficits-A clinical survey on international practice of awake craniotomy and definitions of postoperative "major" and "minor" deficits.

Vooijs M, Robertson F, Blitz S, Jungk C, Krieg S, Schucht P Neurooncol Adv. 2024; 6(1):vdae206.

PMID: 39687790 PMC: 11647522. DOI: 10.1093/noajnl/vdae206.

References

Hatae R, Hata N, Suzuki S, Yoshimoto K, Kuga D, Murata H . A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. Neuropathology. 2016; 37(3):191-199. DOI: 10.1111/neup.12347. View

Lim D, Cha S, Mayo M, Chen M, Keles E, Vandenberg S . Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 2007; 9(4):424-9. PMC: 1994099. DOI: 10.1215/15228517-2007-023. View

Hadjipanayis C, Widhalm G, Stummer W . What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?. Neurosurgery. 2015; 77(5):663-73. PMC: 4615466. DOI: 10.1227/NEU.0000000000000929. View

Eyupoglu I, Hore N, Merkel A, Buslei R, Buchfelder M, Savaskan N . Supra-complete surgery via dual intraoperative visualization approach (DiVA) prolongs patient survival in glioblastoma. Oncotarget. 2016; 7(18):25755-68. PMC: 5041941. DOI: 10.18632/oncotarget.8367. View

Kelly P, Daumas-Duport C, Kispert D, Kall B, Scheithauer B, Illig J . Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987; 66(6):865-74. DOI: 10.3171/jns.1987.66.6.0865. View

Glenn C, Baker C, Conner A, Burks J, Bonney P, Briggs R . An Examination of the Role of Supramaximal Resection of Temporal Lobe Glioblastoma Multiforme. World Neurosurg. 2018; 114:e747-e755. DOI: 10.1016/j.wneu.2018.03.072. View

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H . A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016; 4(1):79. PMC: 4977715. DOI: 10.1186/s40478-016-0351-2. View

Shah A, Mahavadi A, Di L, Sanjurjo A, Eichberg D, Borowy V . Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection. J Neurooncol. 2020; 148(3):501-508. PMC: 7442660. DOI: 10.1007/s11060-020-03541-5. View

Haj A, Doenitz C, Schebesch K, Ehrensberger D, Hau P, Putnik K . Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center. Brain Sci. 2018; 8(1). PMC: 5789336. DOI: 10.3390/brainsci8010005. View

10.

Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein C, Hau P . Tumor Cell Invasion in Glioblastoma. Int J Mol Sci. 2020; 21(6). PMC: 7139341. DOI: 10.3390/ijms21061932. View

11.

John F, Bosnyak E, Robinette N, Amit-Yousif A, Barger G, Shah K . Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival. Neuro Oncol. 2018; 21(2):264-273. PMC: 6374760. DOI: 10.1093/neuonc/noy169. View

12.

Molinaro A, Hervey-Jumper S, Morshed R, Young J, Han S, Chunduru P . Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol. 2020; 6(4):495-503. PMC: 7042822. DOI: 10.1001/jamaoncol.2019.6143. View

13.

Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M . TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2014; 17(1):45-52. PMC: 4483052. DOI: 10.1093/neuonc/nou158. View

14.

Fujioka Y, Hata N, Akagi Y, Kuga D, Hatae R, Sangatsuda Y . Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid. J Neurooncol. 2021; 152(1):47-54. PMC: 7910241. DOI: 10.1007/s11060-020-03682-7. View

15.

Stummer W, Suero Molina E . Fluorescence Imaging/Agents in Tumor Resection. Neurosurg Clin N Am. 2017; 28(4):569-583. DOI: 10.1016/j.nec.2017.05.009. View

16.

Certo F, Altieri R, Maione M, Schonauer C, Sortino G, Fiumano G . FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series. Oper Neurosurg (Hagerstown). 2020; 20(2):151-163. DOI: 10.1093/ons/opaa293. View

17.

Matsuda M, Kohzuki H, Ishikawa E, Yamamoto T, Akutsu H, Takano S . Prognostic analysis of patients who underwent gross total resection of newly diagnosed glioblastoma. J Clin Neurosci. 2018; 50:172-176. DOI: 10.1016/j.jocn.2018.01.009. View

18.

Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y . First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. J Neurooncol. 2020; 146(3):451-458. DOI: 10.1007/s11060-019-03339-0. View

19.

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

20.

Esquenazi Y, Friedman E, Liu Z, Zhu J, Hsu S, Tandon N . The Survival Advantage of "Supratotal" Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. Neurosurgery. 2017; 81(2):275-288. DOI: 10.1093/neuros/nyw174. View